National Delphi consensus study on harmonization of PD-L1 IHC assays for first-line immune checkpoint inhibitor plus chemotherapy in advanced gastric cancer in Korea: A study protocol (KINGCA Week 2026) - Oct 11, 2026 - Abstract #OP2-6; Pres time: Sep 17, 2026; 01:55 PM - 02:02 PM; Location: Room D; "In Korea, where nivolumab and pembrolizumab are already reimbursed and tislelizumab approval is anticipated, harmonization of PD-L1 assessment has become increasingly relevant. This study will provide the first Korean multidisciplinary consensus on PD-L1 assay harmonization in advanced gastric cancer. The findings may serve as a useful reference for future practice guidelines and ongoing evidence development and could help inform the design of subsequent prospective or real-world studies in this evolving area."
Checkpoint inhibition • Clinical • Harmonization • Metastases • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • PD-L1
|
|
Won Jun Seo1; Chang Seok Ko2; Ga Hee Kim3; Ki-Yoon Kim4; Sin Hye Park Park5; Ji-Hyeon Park6; Ba Ool Seong7; Soomin Ahn8; Hyun Lim9; Hyeon-Su Im10; Hye Seung Lee11; Dong-Hoe Koo12
|